Advertisement
Product › Details
SPK-8011 (gene therapy for hemophilia A)
Next higher product group | gene therapy hemophilia A | |
Status | 2018-11-06 development p2 existent | |
Organisation | Spark Therapeutics Inc. | |
Group | Roche (Group) | |
Source | Spark Therapeutics, Inc.. (11/6/18). "Press Release: Spark Therapeutics Reports Third Quarter 2018 Financial Results and Recent Business Progress". Philadeliphia, PA. | |
Record changed: 2023-07-10 |
Advertisement
More documents for gene therapy hemophilia A
- [1] Federal Trade Commission. (12/16/19). "Press Release: Federal Trade Commission Closes Investigation of Roche Holding AG’s Proposed Acquisition of Spark Therapeutics, Inc."....
- [2] Bluebird Bio, Inc.. (10/9/19). "Press Release: Bluebird Bio and Novo Nordisk Enter into Research Agreement to Develop in vivo Genome Editing Candidates for Haemophilia and Other Severe Genetic Diseases". Cambridge, MA & Bagsværd....
- [3] Sangamo Therapeutics, Inc.. (4/2/19). "Press Release: Sangamo and Pfizer Announce Phase 1/2 Interim Data for Investigational Hemophilia A Gene Therapy". Brisbane, CA & New York, NY....
- [4] Roche. (2/25/19). "Press Release: Roche Enters into Definitive Merger Agreement to Acquire Spark Therapeutics". Basel....
- [5] Synpromics Ltd.. (12/5/18). "Press Release: Uniqure Incorporates Novel Synthetic Promoter Developed by Synpromics in New Preclinical Target". Edinburgh....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top